We use cookies to ensure that we give you the best experience on our website Learn more

Jun 19, 2019

MASCC/ISOO Annual Meeting on Supportive Care in Cancer

07 - THE NEGATIVE PROGNOSTIC ROLE OF OPIOIDS IN PATIENTS WITH NSCLC TREATED WITH IMMUNOTHERAPY

;

immunotherapy

nsclc

opioid

prognosis

Abstract

Abstract

thumbnail

Keywords

immunotherapy

nsclc

opioid

prognosis

Abstract

Background: Opioids seem to interfere with immune response. We analysed the prognostic and predictive impact of opioids in Non Small Cell Lung Cancer (NSCLC) patients treated with immunotherapy. Methods: We retrospectively collected and analyzed data about NSCLC patients treated with anti-PD-1/anti-PD-L1 agents at our Institution. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. A Cox regression model was carried out for univariate and multivariate analyses. Results: Sixty-six patients were enrolled, 50 male (75.8%) and 16 female (24.2%). Median age was 72 years (range 25-88). Thirty-one patients (47%) received opioids at the beginning and/or during immunotherapy. This setting of patients had a poorer prognosis (mOS 5.37 months vs not reached, p= 0.0009; mPFS 3.83 months vs not reached, p=0.0001). Performance Status (PS) according to Eastern Cooperative Oncology Group (ECOG) had a prognostic and predictive role (mOS 3.23 months vs not reached, p=0.0059; mPFS of 1.7 vs 3.8 months, p= 0.0089). Sex, age (cut-off 70 years), lymphopenia, PD-L1 expression did not result as prognostic and predictive factors. Multivariate analysis confirmed that opioids had a negative prognostic and predictive role and ECOG-PS ≥2 had a negative prognostic impact. Patients requiring higher opioids doses or opioids switch had a lower survival (OS 4.9 vs 16.5 months; p=0.0030). A trend of worse prognosis was observed in patients receiving morphine (mOS 4.1 vs 8.6 months, p= 0.059) and fentanyl (mOS 4.17 vs 8.63 months). Conclusion: Opioid treatment and its escalation at the beginning and during immunotherapy are negative prognostic factors in advanced NSCLC.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.